Every material Form 8-K REGENXBIO Inc. has filed with the SEC since September 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
REGENXBIO reported third quarter 2026 results with revenue of $9.2 million, down from $29.7 million a year earlier, mainly because ZOLGENSMA royalties fell after U.S. patent expiry in January 2026. The net loss narrowed to $40.7 million, or $0.62 per share, from $61.9 million, or $1.20 per share, helped by a $38.0 million gain on a Sarepta litigation settlement; the company said its cash runway extends into late Q4 2027.
Q3 2026 revenues were $9.2 million versus $29.7 million in Q3 2025; ZOLGENSMA royalty revenue fell $21.2 million.
Net loss was $40.7 million, or $0.62 per share, versus $61.9 million, or $1.20 per share, a year earlier.
Q3 included a $38.0 million gain on the Sarepta settlement; the $39.0 million payment was received in October 2026.
Cash, cash equivalents and marketable securities were $251.0 million at September 30, 2026; the company expects this plus the settlement proceeds to fund operations into late Q4 2027.
REGENXBIO's board director Kenneth T. Mills resigned effective October 21, 2026, saying he became CEO of another company and will focus on that role, not on any disagreement with the company. The board named George Migausky as Chairman, and Daniel Tassé stepped down as Lead Independent Director but remains on the board. The change is a board governance update with no financial figures disclosed.
Kenneth T. Mills resigned from the board on October 14, 2026, effective October 21, 2026
Mr. Mills cited his new role as chief executive officer of another company; filing says no disagreement with the company
George Migausky appointed Chairman of the Board
Daniel Tassé stepped down as Lead Independent Director under the Corporate Governance Guidelines and remains a director
REGENXBIO and the University of Pennsylvania agreed to settle patent infringement litigation with Sarepta Therapeutics and Catalent over Sarepta's ELEVIDYS gene therapy. Sarepta will pay REGENXBIO $39.0 million within 10 days of the settlement's effective date, and the parties will end the ongoing patent litigation.
Sarepta will pay $39.0 million to REGENXBIO within 10 days of the settlement's effective date.
The settlement covers U.S. Patent No. 10,526,617 and U.S. Patent No. 11,680,274, related to SRP-9001 (ELEVIDYS).
REGENXBIO and UPenn release current infringement claims and agree to a covenant not to sue for future claims on AAVrh74-based Sarepta gene therapy products.
The full agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every REGENXBIO Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →